Deal-Making Archives - Page 21 of 59 - BioProcess InternationalBioProcess International

Stirling Ultracold fifth acquisition in 2 years for BioLife

Supplier of services and bioproduction tools BioLife Solutions has merged with developer and manufacturer of ultra-low temperature freezers Stirling Ultracold. “We continue to execute on our M&A strategy with another acquisition that superbly complements our product portfolio. Combining Stirling’s -20°C to -86°C freezer systems with our liquid nitrogen products provides complete ultra-low temperature cold-chain infrastructure critical for personalized medicine,” said BioLife’s CEO, Mike Rice. The transaction is expected to close during the early second quarter of 2021 with BioLife planning…

WuXi Bio set for 430,000 L biomanufacturing capacity from 2024

by Dan Stanton

The acquisition of CMAB Biopharma comes days after WuXi Biologics bought a Pfizer facility, months after it added a Bayer plant, and a decade after it entered the biomanufacturing space. Contract development and manufacturing organization (CDMO) is in the news again, just a week after it acquired a single-use biologics manufacturing plant in Hangzhou, China from Big Pharma firm Pfizer. This time it has entered an agreement to buy over 90% of fellow Chinese CDMO CMAB Biopharma for an undisclosed…

Catalent increases capacity in Italy for J&J’s COVID vaccine

by Millie Nelson

Catalent will add a high-speed vial-filling line to increase its manufacturing capacity for J&J’s single-shot COVID-19 vaccine. The expanded partnership will see contract development manufacturing organization (CDMO) Catalent add an additional high-speed vial-filling line at its site in Anagni, Italy. The line is set to be operational by the fourth quarter of 2021 and support the making of Johnson & Johnson’s (J&J) COVID-19 vaccine throughout 2022. The CDMO said the increase in its manufacturing capacity at the 300,000 square-foot Italian…

Takeda loans J&J CDMO space to support COVID vaccine roll out

by Millie Nelson

IDT Biologika will use capacity reserved for Takeda’s dengue vaccine candidate to provide fill-finish for Johnson & Johnson’s COVID-19 single-shot jab. Contract development manufacturing organization (CDMO) IDT Biologika had been contracted to use its Dessau site in Germany to manufacture Takeda’s dengue vaccine candidate, TAK-003. However, the facility will now be dedicated to filling and packaging J&J’s vaccine, which received US Food and Drug Administration (FDA) approval in February this year. J&J’s vaccine will be manufactured at the Dessau site…

Lonza dedicates suite to make Altimmune’s nasal COVID-19 vaccine

by Millie Nelson

Lonza will commission a dedicated suite at its Houston, US facility for supply of Altimmune’s AdCOVID, a nasal COVID-19 vaccine that entered Phase I trials last month. Last November, Altimmune entered an agreement which meant that Lonza would provide commercial production capacity for AdCOVID from its Houston, US, site. Now, Altimmune has expanded its manufacturing partnership with lonza by adding capacity and stability through its own dedicated suite. “Our recently inaugurated Houston facility is our center of excellence for process…

Ins & Outs: Ex-Lonza CEO joins Recipharm, plus changes at Moderna

by Millie Nelson

Marc Funk has joined CDMO Recipharm as its new CEO, while Moderna pinches Novartis’s chief legal officer. Meanwhile, there are high level changes at Univercells Technologies. It’s lovely to have you here for another BioProcess Insider’s, Ins & Outs. This week, Marc Funk announced on LinkedIn that he has joined Recipharm as CEO. Funk has replaced contract development manufacturing organization (CDMO) Recipharm’s former CEO, Thomas Eldered who had held this position since 2008. “It is a great pleasure to be…

Pfizer exits Chinese biosimilars space, selling plant to WuXi

by Dan Stanton

As part of a “difficult decision” to halt its biosimilars programs in China, Pfizer is offloading its single-use biologics manufacturing plant in Hangzhou to WuXi Biologics. Pfizer is one of the world’s largest biosimilar manufacturers, with seven commercialized products in the US alone (Inflectra, Retacrit, Nivestym, Nyvepria, Zirabev, Trazimera, Ruxience). In 2016, Pfizer took aim at the Chinese market by investing $350 million in the Hangzhou Economic Development Area (HEDA) to set up a biosimilars manufacturing facility. Five years on…

Industry hot for cold chain technologies, says thermal packaging firm

by Millie Nelson

Cold Chain Technologies has scaled-up capacity after seeing an unprecedented demand for its services during the coronavirus pandemic. The thermal packaging solutions company, Cold Chain Technologies is part of the US government’s Operation Warp Speed (OWS) vaccine distribution plan and director of Corporate Development, Jamie Chasteen told BioProcess Insider it has seen a “huge bump” in demand since COVID-19. To meet this demand, the firm opened a manufacturing plant in less than eight weeks in Lebanon, Tennessee in November 2020…

ConserV Bioscience and eTheRNA to develop HIV vaccine

by Millie Nelson

ConserV Bioscience and eTheRNA will share their expertise to develop an mRNA-based vaccine for HIV. The partnership will bring together ConserV’s services in identifying protective antigens and eTheRNA’s TriMix immunostimulatory mRNA technology and novel lipid nanoparticle encapsulation technologies. “We will first collaborate on an mRNA vaccine against HIV,” Tim Van Assche, director of Business Development and Alliance Management at eTheRNA Immunotherapies told BioProcess Insider. “In case results are positive, the collaboration will be extended to other mRNA vaccine formulations based…

Univercells Technologies teams with High Purity New England for distribution

by Millie Nelson

High Purity New England (HPNE) will market and sell Univercells Technologies’ products in the US after the two firms enter an agreement. No financials are connected to the agreement, however HPNE is now an authorized distributor of the firm’s technology offerings, which includes the Nevoline Upstream platform, the scale-X carbo system, and the scale-X hydro system. “The goal is to increase reach, expand the sales pipeline and further build the supply and service organization, recognizing the importance of being closer…